Evolus Nuceiva nod in Europe may be extended 90 days

Evolus (EOLS -1.4%) reports that the expected approval of Nuceiva (prabotulinumtoxinA-xvfs)(branded as Jeuveau in the U.S.) by the European Commission may be delayed 90 days to allow it to review supplementary information that it requested from the European Medicines Agency and its advisory group CHMP.

In late April, CHMP adopted a positive opinion backing approval.

https://seekingalpha.com/news/3470122-nuceiva-nod-europe-may-extended-90-days